Nathaniel Simons
Meritage Group
Nathaniel Simons Charles River Laboratories stake
total: 301
Meritage Group CRL trades
- Total transactions:
- 7
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 1
- Held since:
- 2023 Q3
- Held for:
- 6 quarters
- Latest activity:
- 2025 Q1
According to 2026 Q1 report, Nathaniel Simons doesn't hold any Charles River Laboratories (CRL) shares. To date, the estimated cost basis is nearly $206.95 for "buy" trades and estimated average "sell" price is $184.6. Meritage Group first purchased CRL in 2023 Q3, initially acquiring 883,633 shares. Since the initial investment in Charles River Laboratories (CRL), Meritage Group has made 6 more transactions.
When did Nathaniel Simons sell Charles River Laboratories (CRL)?
Nathaniel Simons sold off the entire Charles River Laboratories (CRL) position in 2025 Q1.
When did Nathaniel Simons buy Charles River Laboratories (CRL)?
Nathaniel Simons first invested in Charles River Laboratories (CRL) in 2023 Q3 at the reported quarter-end price of $195.98 per share.
What's the cost basis of Meritage Group's CRL stake?
The estimated cost basis for Charles River Laboratories (CRL) stake is around $206.95 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $206.95
- Weighted AVG sell price:
- $184.60
Nathaniel Simons's historical trades in Charles River Laboratories
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.00%
|
0
|
$184.60
|
|
-100% (-1,074,120)
|
-4.73%
|
|
2024 Q4
|
4.73%
|
1,074,120
|
$184.60
|
$198,282,552
|
-9.37% (-111,047)
|
-0.48%
|
|
2024 Q3
|
5.45%
|
1,185,167
|
$196.97
|
$233,442,344
|
+0.21% (+2,510)
|
+0.01%
|
|
2024 Q2
|
6.21%
|
1,182,657
|
$206.58
|
$244,313,283
|
+0.03% (+389)
|
+0%
|
|
2024 Q1
|
7.54%
|
1,182,268
|
$270.95
|
$320,336,000
|
+2.33% (+26,892)
|
+0.17%
|
|
2023 Q4
|
6.29%
|
1,155,376
|
$236.40
|
$273,131,000
|
+30.75% (+271,743)
|
+1.48%
|
|
2023 Q3
|
4.74%
|
883,633
|
$195.98
|
$173,174,000
|
new
|
+4.74%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.